2023 World Conference on Lung Cancer (Posters)-EP13.03. Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC

EP13.03. Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC - PDF(Slides)

Pdf Summary

A study was conducted to evaluate the efficacy and safety of tislelizumab plus etoposide and carboplatin as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Tislelizumab is a monoclonal antibody that targets PD-1 and is currently approved for various indications excluding ES-SCLC.<br /><br />The study enrolled 8 patients, primarily males with a median age of 65.4 years and a smoking history. The patients received 4 cycles of tislelizumab, etoposide, and carboplatin, followed by tislelizumab maintenance until disease progression or intolerable side effects. The median follow-up was 9.55.3 months.<br /><br />The primary endpoint of the study was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs). The study found promising efficacy, with an ORR of 62.5% and a disease control rate (DCR) of 87.5%. However, 50% of the patients experienced disease progression during the follow-up period. The median PFS was 14.3 months, and the median OS was not reached.<br /><br />Radiographic imaging was performed at baseline and at regular intervals up to 2 years from randomization. The study was supported by the National Natural Science Foundation of China.<br /><br />In conclusion, tislelizumab plus etoposide and carboplatin showed promising efficacy and acceptable safety as a first-line treatment for ES-SCLC. The study is still ongoing, and long-term efficacy, such as overall survival, will be evaluated in the future.

Asset Subtitle

Chu Qian

Meta Tag

Speaker Chu Qian

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

tislelizumab

etoposide

carboplatin

first-line treatment

extensive-stage small-cell lung cancer

efficacy

safety

monoclonal antibody

overall survival

progression-free survival